Treatment

Orforglipron clinical trials

Active studies that list Orforglipron as an intervention or treatment.

21active studies

7recruiting now

20countries represented

566largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Atherosclerosis Cardiovascular Disease, Chronic Kidney DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina566 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07241390See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

Diabetes Mellitus, Type 2, Diabetes MelletusCondition

OrforglipronTreatment

India, Saudi Arabia40 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07613307See eligibility →

Recruiting nowPhase 3

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Belgium, Brazil117 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672549See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Opening soonPhase 4

PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

Diabete Type 2, Pharmacogenomic Drug InteractionCondition

OrforglipronTreatment

Locations pending0 locations

Massachusetts General HospitalSponsor

Updated 2026-08-31 · NCT07739537See eligibility →

Opening soonPhase 1

IBI3042 Study in Healthy Participants and Overweight or Obese Participants

Overweight, Healthy ParticipantsCondition

Orforglipron, Matching PlaceboTreatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2026-08-28 · NCT07793019See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

China13 locations

Eli Lilly and CompanySponsor

Updated 2026-08-27 · NCT07790861See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Orforglipron, DulaglutideTreatment

Belgium, Brazil71 locations

Eli Lilly and CompanySponsor

Updated 2026-08-19 · NCT07668336See eligibility →

Opening soonPhase 4

Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation

ObesityCondition

Phentermine Pill, OrforglipronTreatment

United States1 locations

Massachusetts General HospitalSponsor

Updated 2026-07-27 · NCT07729332See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China100 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948422See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Hypertension, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948435See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06952530See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

OSA, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, Brazil66 locations

Eli Lilly and CompanySponsor

Updated 2025-09-29 · NCT06649045See eligibility →

Related treatments

Placebo421 Tirzepatide119 Semaglutide91 Control30 Exercise27

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.